



Clinical trial results:

A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer Summary

EudraCT number	2018-004040-28
Trial protocol	BE
Global end of trial date	29 July 2022

Results information

Result version number	v1 (current)
This version publication date	06 August 2023
First version publication date	06 August 2023

Trial information

Trial identification

Sponsor protocol code	MS200647_0024
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03840915
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Healthcare KGaA, Darmstadt, Germany
Sponsor organisation address	Frankfurter Strasse 250, Darmstadt, Germany, 64293
Public contact	Communication Center, Merck Healthcare KGaA, Darmstadt, Germany, +49 6151725200, service@merckgroup.com
Scientific contact	Communication Center, Merck Healthcare KGaA, Darmstadt, Germany, +49 6151725200, service@merckgroup.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 July 2022
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	29 July 2022
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The main purpose of the study is to evaluate the safety and tolerability of M7824 in combination with chemotherapy.

Protection of trial subjects:

Subject protection was ensured by following high medical and ethical standards in accordance with the principles laid down in the Declaration of Helsinki, and that are consistent with Good Clinical Practice and applicable regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 April 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 42
Country: Number of subjects enrolled	United States: 18
Country: Number of subjects enrolled	Belgium: 10
Worldwide total number of subjects	70
EEA total number of subjects	52

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	40
From 65 to 84 years	30

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 127 subjects were screened out of which 70 subjects received study intervention.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cohort A: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed

Arm description:

Subjects received 2400 milligrams (mg) Bintrafusp alfa along with Cisplatin 75 mg/ m² (per meter square) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed at a dose of 500 mg/ m² over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days) until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Arm type	Experimental
Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m²) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bintrafusp alfa will be administered intravenously at a dose of 2400 mg Bintrafusp alfa every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with Bintrafusp alfa and pemetrexed.

Investigational medicinal product name	Pemetrexed
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Pemetrexed will be administered intravenously at a dose of 500 mg/ m² over 10 minutes every 21 days.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion

Routes of administration	Intravenous use
--------------------------	-----------------

Dosage and administration details:

Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Arm title	CohortB:Bintrafusp alfa+Carboplatin+Paclitaxel/Nab-paclitaxel
------------------	---

Arm description:

Subjects received 2400 mg Bintrafusp alfa along with Carboplatin at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel at as dose of 100 mg/m² over 30 to 60 minutes (Nab- paclitaxel was administered on Day 1, 8, and 15), and Paclitaxel at a dose of 200 mg/m² over 3 hours every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Arm type	Experimental
Investigational medicinal product name	Nab-paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Nab-paclitaxel will be administered intravenously at as dose of 100 mg/m² over 30 minutes in a 21 days cycle on Day 1, 8, and 15 in each cycle for 4 cycles (each cycle is 21 days).

Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bintrafusp alfa will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with Bintrafusp alfa alone.

Investigational medicinal product name	Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Paclitaxel will be administered intravenously at a dose of 200 mg/m² over 3 hours every 3 weeks for 4 cycles (each cycle is 21 days).

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin will be administered at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Arm title	CohortC:Bintrafusp alfa+Cisplatin/Carboplatin+Gemcitabine
------------------	---

Arm description:

Subjects received 2400 mg Bintrafusp alfa along with Cisplatin at a dose of 75 milligrams per meter square (mg/m²) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine at a dose of 1250 mg/m² over 30 to 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin will be administered intravenously at a dose of 75 milligrams per meter square (mg/m^2) over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bintrafusp alfa will be administered intravenously at a dose of 2400 mg every 21 days in combination with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with Bintrafusp alfa alone.

Investigational medicinal product name	Carboplatin
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Carboplatin will be administered at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Investigational medicinal product name	Gemcitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Gemcitabine will be administered intravenously at a dose of $1250 \text{ mg}/\text{m}^2$ over 30 minutes in a 21 days cycle on Day 1, and 8, in each cycle for 4 cycles (each cycle is 21 days).

Arm title	Cohort D: Bintrafusp alfa + Docetaxel
------------------	---------------------------------------

Arm description:

Subjects received 2400 mg Bintrafusp alfa along with Docetaxel at a dose of $75 \text{ mg}/\text{m}^2$ over 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Arm type	Experimental
Investigational medicinal product name	Docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Docetaxel will be administered intravenously at a dose of $75 \text{ mg}/\text{m}^2$ over 60 minutes every 21 days for 4 cycles (each cycle is 21 days).

Investigational medicinal product name	Bintrafusp alfa
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

Bintrafusp alfa will be administered intravenously at a dose of 2400 mg every 21 days in combination

with chemotherapy for 4 cycles (each cycle is 21 days) followed by up to 31 cycles in maintenance with Bintrafusp alfa alone.

Number of subjects in period 1	Cohort A: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed	CohortB:Bintrafusp alfa+Carboplatin+Paclitaxel/Nab-paclitaxel	CohortC:Bintrafusp alfa+Cisplatin/Carboplatin+Gemcitabine
Started	40	9	9
Safety Analysis Set	40	9	9
Full Analysis Set	40	9	9
Completed	40	9	9

Number of subjects in period 1	Cohort D: Bintrafusp alfa + Docetaxel
Started	12
Safety Analysis Set	12
Full Analysis Set	12
Completed	12

Baseline characteristics

Reporting groups

Reporting group title	Cohort A: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed
-----------------------	--

Reporting group description:

Subjects received 2400 milligrams (mg) Bintrafusp alfa along with Cisplatin 75 mg/ m² (per meter square) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed at a dose of 500 mg/ m² over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days) until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group title	CohortB:Bintrafusp alfa+Carboplatin+Paclitaxel/Nab-paclitaxel
-----------------------	---

Reporting group description:

Subjects received 2400 mg Bintrafusp alfa along with Carboplatin at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel at as dose of 100 mg/m² over 30 to 60 minutes(Nab- paclitaxel was administered on Day 1, 8, and 15), and Paclitaxel at a dose of 200 mg/m² over 3 hours every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group title	CohortC:Bintrafusp alfa+Cisplatin/Carboplatin+Gemcitabine
-----------------------	---

Reporting group description:

Subjects received 2400 mg Bintrafusp alfa along with Cisplatin at a dose of 75 milligrams per meter square (mg/m²) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine at a dose of 1250 mg/m² over 30 to 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group title	Cohort D: Bintrafusp alfa + Docetaxel
-----------------------	---------------------------------------

Reporting group description:

Subjects received 2400 mg Bintrafusp alfa along with Docetaxel at a dose of 75 mg/m² over 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group values	Cohort A: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed	CohortB:Bintrafusp alfa+Carboplatin+Paclitaxel/Nab-paclitaxel	CohortC:Bintrafusp alfa+Cisplatin/Carboplatin+Gemcitabine
Number of subjects	40	9	9
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	20	6	5
From 65-84 years	20	3	4
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	63	64	61
standard deviation	± 10.3	± 8.7	± 11.2
Sex: Female, Male Units: Subjects			
Female	9	3	4

Male	31	6	5
------	----	---	---

Race			
Units: Subjects			
White	14	6	2
Black or African American	1	2	0
Asian	0	0	0
American Indian or Alaska Native	0	0	0
Native Hawaiian or Other Pacific	0	0	0
Not collected at this site	25	1	6
More than one race	0	0	0
Other	0	0	1
Missing	0	0	0
Ethnicity - Hispanic or Latino			
Units: Subjects			
Yes	0	0	0
No	15	8	3
Missing	25	1	6

Reporting group values	Cohort D: Bintrafusp alfa + Docetaxel	Total	
Number of subjects	12	70	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	9	40	
From 65-84 years	3	30	
85 years and over	0	0	
Age Continuous			
Units: Years			
arithmetic mean	60		
standard deviation	± 7.7	-	
Sex: Female, Male			
Units: Subjects			
Female	7	23	
Male	5	47	
Race			
Units: Subjects			
White	3	25	
Black or African American	0	3	
Asian	0	0	
American Indian or Alaska Native	0	0	
Native Hawaiian or Other Pacific	0	0	
Not collected at this site	9	41	

More than one race	0	0	
Other	0	1	
Missing	0	0	
Ethnicity - Hispanic or Latino			
Units: Subjects			
Yes	0	0	
No	3	29	
Missing	9	41	

End points

End points reporting groups

Reporting group title	Cohort A: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed
Reporting group description: Subjects received 2400 milligrams (mg) Bintrafusp alfa along with Cisplatin 75 mg/ m ² (per meter square) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed at a dose of 500 mg/ m ² over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days) until confirmed disease progression, unacceptable toxicity, study withdrawal or death.	
Reporting group title	CohortB:Bintrafusp alfa+Carboplatin+Paclitaxel/Nab-paclitaxel
Reporting group description: Subjects received 2400 mg Bintrafusp alfa along with Carboplatin at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel at as dose of 100 mg/m ² over 30 to 60 minutes(Nab- paclitaxel was administered on Day 1, 8, and 15), and Paclitaxel at a dose of 200 mg/m ² over 3 hours every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.	
Reporting group title	CohortC:Bintrafusp alfa+Cisplatin/Carboplatin+Gemcitabine
Reporting group description: Subjects received 2400 mg Bintrafusp alfa along with Cisplatin at a dose of 75 milligrams per meter square (mg/m ²) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine at a dose of 1250 mg/m ² over 30 to 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.	
Reporting group title	Cohort D: Bintrafusp alfa + Docetaxel
Reporting group description: Subjects received 2400 mg Bintrafusp alfa along with Docetaxel at a dose of 75 mg/m ² over 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.	

Primary: Number of Subjects With Dose-Limiting Toxicities (DLTs)

End point title	Number of Subjects With Dose-Limiting Toxicities (DLTs) ^[1]
End point description: DLT was any AEs with Grade 4 nonhematologic toxicity or hematologic toxicity lasting ≥ 7 days Grade 3 nausea, vomiting, and diarrhea lasting ≥ 3 days Any Grade 3 or Grade 4 nonhematologic lab value leading to hospitalization or persisting for ≥ 7 days Grade 3 or Grade 4: grade 3 is defined as ANC $< 1,000/\text{mm}^3$ with a temperature of $> 38.3^\circ\text{C}$ grade 4 is defined as ANC $< 1,000/\text{mm}^3$ with a temp of $> 38.3^\circ\text{C}$, with life-threatening consequences Thrombocytopenia $< 25,000/\text{mm}^3$ associated with bleeding not resulting in hemodynamic instability or a life-threatening bleeding resulting in urgent intervention; Bleeding events \geq Grade 3 occurring within 5 days of treatment; Prolonged delay in initiating Cycle 2 due to treatment-related toxicity; Grade 5 toxicity. DLT Set included all who received at least 90 % of the infusion and all other planned study administrations during the DLT observation period of 3 weeks and who did not discontinue the study for other reasons than DLT during the first cycle.	
End point type	Primary
End point timeframe: Day 1 Week 1 up to Week 3	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical and comparison analysis were performed in single arm for this endpoint.

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB:Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC:Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	8	8	11
Units: Subjects	1	1	0	3

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs ^[2]
-----------------	--

End point description:

An AE was defined as any untoward medical occurrence in a subject administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether considered related to the medicinal product or protocol-specified procedure. Serious AE was defined AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial/prolonged inpatient hospitalization; congenital anomaly/birth defect. TEAE was defined as events with onset date or worsening during the on-treatment period. TEAEs included serious TEAEs and non-serious TEAEs. The full analysis set (FAS) included all subjects who were administered any dose of any study intervention (bintrafusp alfa or one of the chemotherapies).

End point type	Primary
----------------	---------

End point timeframe:

Time from first treatment assessed up to approximately 26 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical and comparison analysis were performed in single arm for this endpoint.

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB:Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC:Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	9	9	12
Units: Subjects				
TEAEs	40	9	9	12
Serious TEAEs	31	5	6	9

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator (IRC)

End point title	Percentage of Subjects With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator (IRC)
-----------------	--

End point description:

Percentage of subjects with confirmed objective response that is at least one overall assessment of complete response (CR) or partial response (PR) reported here. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Confirmed CR = at least 2 determinations of CR at least 4 weeks apart and before progression. Confirmed PR = at least 2 determinations of PR at least 4 weeks apart and before progression (and not qualifying for a CR). Confirmed objective response was determined according to RECIST v1.1 and as adjudicated by Investigator. The full analysis set (FAS) included all subjects who were administered any dose of any study intervention (bintrafusp alfa or one of the chemotherapies).

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first treatment assessed up to approximately 26 months

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB:Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC:Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	9	9	12
Units: Percentage of Subjects				
number (confidence interval 95%)	45.0 (29.3 to 61.5)	66.7 (29.9 to 92.5)	44.4 (13.7 to 78.8)	16.7 (2.1 to 48.4)

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator

End point title	Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator
-----------------	---

End point description:

PFS was defined as the time from first administration of study intervention until date of the first documentation of disease progression (PD) or death due to any cause, whichever occurred first. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Kaplan-Meier estimates was used to calculate PFS. The full analysis set (FAS) included all subjects who were administered any dose of any study intervention (bintrafusp alfa or one of the chemotherapies)

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first administration of study drug until the first documentation of PD or death, assessed approximately 26 months

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	9	9	12
Units: months				
median (confidence interval 95%)	5.0 (0.0 to 14.3)	4.1 (1.2 to 17.7)	5.4 (1.4 to 19.6)	2.6 (1.3 to 10.4)

Statistical analyses

No statistical analyses for this end point

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description:	
OS was defined as the time from first administration of study intervention to the date of death due to any cause. The OS was analyzed by using the Kaplan-Meier method. The full analysis set (FAS) included all subjects who were administered any dose of any study intervention (bintrafusp alfa or one of the chemotherapies). 9.99999 represents no observation.	
End point type	Secondary
End point timeframe:	
Time from first treatment assessed up to approximately 26 months	

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	9 ^[3]	9 ^[4]	12 ^[5]
Units: months				
median (confidence interval 95%)	11.4 (6.4 to 15.1)	11.8 (1.9 to 99999)	99999 (5.7 to 99999)	16.5 (3.0 to 99999)

Notes:

[3] - Due to small number of events, estimate from Kaplan-Meier survival curves could not be derived.

[4] - Due to small number of events, estimate from Kaplan-Meier survival curves could not be derived.

[5] - Due to small number of events, estimate from Kaplan-Meier survival curves could not be derived.

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
-----------------	----------------------------

End point description:

DOR was defined for subjects with confirmed response, as the time from first documentation of confirmed objective response (Complete Response [CR] or Partial Response [PR]) according to RECIST 1.1 to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the SLD of all lesions. PD: At least a 20 percent (%) increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. Results were calculated based on Kaplan-Meier estimates. The full analysis set (FAS) included all subjects who were administered any dose of any study intervention (bintrafusp alfa or one of the chemotherapies). 9.99999 represents no observation.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first documentation of a confirmed objective response to PD or death due to any cause (assessed up to approximately 26 months)

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB:Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC:Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40 ^[6]	9 ^[7]	9 ^[8]	12
Units: months				
median (confidence interval 95%)	9.6 (3.7 to 99999)	99999 (2.8 to 99999)	10.5 (2.8 to 99999)	3.4 (3.0 to 3.8)

Notes:

[6] - Due to small number of events, estimate from Kaplan-Meier survival curves could not be derived.

[7] - Due to small number of events, estimate from Kaplan-Meier survival curves could not be derived.

[8] - Due to small number of events, estimate from Kaplan-Meier survival curves could not be derived.

Statistical analyses

No statistical analyses for this end point

Secondary: Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Bintrafusp Alfa

End point title	Immediate Observed Serum Concentration at End of Infusion (Ceoi) of Bintrafusp Alfa
-----------------	---

End point description:

Ceoi was the observed concentration at the end of the infusion period. This was taken directly from the observed Bintrafusp Alfa concentration-time data.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose, Day 22, Day 43, Day 64 and Day 85

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB:Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC:Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[9]	0 ^[10]	0 ^[11]	0 ^[12]
Units: microgram per milliliter (mcg/mL)				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[9] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[10] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[11] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[12] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Serum Trough Concentration Levels (C_{trough}) of Bintrafusp Alfa

End point title	Serum Trough Concentration Levels (C _{trough}) of Bintrafusp Alfa
End point description:	C _{trough} was the serum concentration observed immediately before next dosing.
End point type	Secondary
End point timeframe:	Predose, Day 22, Day 43, Day 64 and Day 85

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB:Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC:Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[13]	0 ^[14]	0 ^[15]	0 ^[16]
Units: mcg/mL				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[13] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[14] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[15] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[16] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Bintrafusp Alfa

End point title	Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Bintrafusp Alfa
-----------------	--

End point description:

The area under the concentration-time curve (AUC) from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification. Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

End point type	Secondary
----------------	-----------

End point timeframe:

Predose, Day 22, Day 43, Day 64 and Day 85

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed	CohortB:Bintrafusp alfa+Carboplatin+Paclitaxel/Nab-paclitaxel	CohortC:Bintrafusp alfa+Cisplatin/Carboplatin+Gemcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[17]	0 ^[18]	0 ^[19]	0 ^[20]
Units: nanogram hour per milliliter (ng*h/mL)				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[17] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[18] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[19] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[20] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Bintrafusp Alfa

End point title	Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Bintrafusp Alfa
-----------------	--

End point description:

The AUC from time zero (dosing time) extrapolated to infinity, based on the predicted value for the concentration at tlast, as estimated using the linear regression from terminal first order (elimination) rate constant determination. $AUC0-inf = AUC0-tlast + C_{last} \text{ pred} / \text{terminal first order (elimination) rate constant}$.

End point type	Secondary
----------------	-----------

End point timeframe:

Predose, Day 22, Day 43, Day 64 and Day 85

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[21]	0 ^[22]	0 ^[23]	0 ^[24]
Units: ng*h/mL				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[21] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[22] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[23] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[24] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum Observed Plasma Concentration (Cmax) of Bintrafusp Alfa

End point title	Maximum Observed Plasma Concentration (Cmax) of Bintrafusp Alfa
End point description:	
Cmax was obtained directly from the concentration versus time curve.	
End point type	Secondary
End point timeframe:	
Predose, Day 22, Day 43, Day 64 and Day 85	

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[25]	0 ^[26]	0 ^[27]	0 ^[28]
Units: ng/mL				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[25] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[26] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[27] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

collected.

[28] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Reach Maximum Plasma Concentration (Tmax) of Bintrafusp Alfa

End point title	Time to Reach Maximum Plasma Concentration (Tmax) of Bintrafusp Alfa
End point description: The time to reach the maximum observed concentration collected during a dosing interval. Tmax was obtained directly from the concentration versus time curve.	
End point type	Secondary
End point timeframe: Predose, Day 22, Day 43, Day 64 and Day 85	

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[29]	0 ^[30]	0 ^[31]	0 ^[32]
Units: hour				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

[29] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[30] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[31] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[32] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Terminal Elimination Half-Life (T1/2) of Bintrafusp Alfa

End point title	Terminal Elimination Half-Life (T1/2) of Bintrafusp Alfa
End point description: Elimination half-life determined as 0.693/terminal first order (elimination) rate constant.	
End point type	Secondary
End point timeframe: Predose, Day 22, Day 43, Day 64 and Day 85	

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[33]	0 ^[34]	0 ^[35]	0 ^[36]
Units: hour				
geometric mean (geometric coefficient of variation)	()	()	()	()

Notes:

[33] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[34] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[35] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

[36] - The sponsor decided to restrict the analysis of Pharmacokinetics (PK) and no PK data was collected.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Positive Antidrug Antibodies (ADA)

End point title	Number of Subjects With Positive Antidrug Antibodies (ADA)
-----------------	--

End point description:

Serum samples were analyzed by a validated assay method to detect the presence of antidrug antibodies (ADA). Number of subjects with positive ADA were reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Time from first treatment and assessed up to Disease Progression or End of Treatment

End point values	Cohort A: Bintrafusp alfa + Cisplatin/Carbo platin + Pemetrexed	CohortB: Bintraf usp alfa+Carboplati n+Paclitaxel/N ab-paclitaxel	CohortC: Bintraf usp alfa+Cisplatin/ Carboplatin+G emcitabine	Cohort D: Bintrafusp alfa + Docetaxel
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	38	9	8	12
Units: Subjects	9	3	2	3

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Time from first treatment assessed up to approximately 26 months

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

Reporting groups

Reporting group title	CohortA: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed
-----------------------	---

Reporting group description:

Subjects received 2400 milligrams (mg) Bintrafusp alfa along with Cisplatin 75 mg/ m² (per meter square) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with pemetrexed at a dose of 500 mg/ m² over 30 to 60 minutes every 21 days for 4 cycles (each cycle is 21 days) until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group title	CohortB: Bintrafusp alfa + Carboplatin + Paclitaxel or Nab-paclitaxel
-----------------------	---

Reporting group description:

Subjects received 2400 mg Bintrafusp alfa along with Carboplatin at area under the concentration-time Curve (AUC) 6 when combined with nab-paclitaxel at as dose of 100 mg/m² over 30 to 60 minutes (Nab- paclitaxel was administered on Day 1, 8, and 15), and Paclitaxel at a dose of 200 mg/m² over 3 hours every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group title	CohortC: Bintrafusp alfa + Cisplatin/Carboplatin + Gemcitabine
-----------------------	--

Reporting group description:

Subjects received 2400 mg Bintrafusp alfa along with Cisplatin at a dose of 75 milligrams per meter square (mg/m²) over 60 minutes or Carboplatin at area under the concentration-time Curve (AUC) 5 when combined with gemcitabine at a dose of 1250 mg/m² over 30 to 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Reporting group title	Cohort D: Bintrafusp alfa + Docetaxel
-----------------------	---------------------------------------

Reporting group description:

Subjects received 2400 mg Bintrafusp alfa along with Docetaxel at a dose of 75 mg/m² over 60 minutes every 21 days for 4 cycles until confirmed disease progression, unacceptable toxicity, study withdrawal or death.

Serious adverse events	CohortA: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed	CohortB: Bintrafusp alfa + Carboplatin + Paclitaxel or Nab-paclitaxel	CohortC: Bintrafusp alfa + Cisplatin/Carboplatin + Gemcitabine
Total subjects affected by serious adverse events			
subjects affected / exposed	31 / 40 (77.50%)	5 / 9 (55.56%)	6 / 9 (66.67%)
number of deaths (all causes)	23	4	4
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to central nervous system			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Metastases to bone			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of the tongue			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemodynamic instability			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Disease progression			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Pyrexia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Pneumothorax			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated lung disease			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute pulmonary oedema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Alanine aminotransferase increased subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Atrial fibrillation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Myelosuppression			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile bone marrow aplasia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pancytopenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bicytopenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic cytolysis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Tubulointerstitial nephritis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephritis			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthralgia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Immune-mediated myositis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone lesion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemophilus sepsis			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pseudomonal			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Yersinia bacteraemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Decreased appetite			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort D: Bintrafusp alfa + Docetaxel		
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 12 (75.00%)		
number of deaths (all causes)	6		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Metastases to central nervous system			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metastases to bone			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of the oral cavity			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of the tongue			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemodynamic instability			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral ischaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral arterial occlusive disease			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Disease progression			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oedema peripheral			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			

Pneumothorax				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	1 / 12 (8.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary oedema				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemoptysis				
subjects affected / exposed	3 / 12 (25.00%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Immune-mediated lung disease				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute pulmonary oedema				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute respiratory distress syndrome				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic obstructive pulmonary disease				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Investigations				

Alanine aminotransferase increased subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutrophil count decreased subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Platelet count decreased subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haematoma subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocarditis subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Atrial fibrillation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Myelosuppression			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Febrile bone marrow aplasia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		

Pancytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bicytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain upper			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Melaena			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Enteritis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Stomatitis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Hepatic cytolysis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Tubulointerstitial nephritis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Nephritis			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthralgia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myositis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Immune-mediated myositis				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bone lesion				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain in extremity				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Cellulitis				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19 pneumonia				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	1 / 12 (8.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Endocarditis				
subjects affected / exposed	1 / 12 (8.33%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Haematoma infection				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemophilus sepsis				

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia pseudomonal			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Spinal cord infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Yersinia bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Decreased appetite			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dehydration			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	CohortA: Bintrafusp alfa + Cisplatin/Carboplatin + Pemetrexed	CohortB: Bintrafusp alfa + Carboplatin + Paclitaxel or Nab-paclitaxel	CohortC: Bintrafusp alfa + Cisplatin/Carboplatin + Gemcitabine
Total subjects affected by non-serious adverse events			
subjects affected / exposed	40 / 40 (100.00%)	9 / 9 (100.00%)	9 / 9 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Cancer pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Keratoacanthoma			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	4 / 9 (44.44%)
occurrences (all)	2	11	15
Papilloma			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pyogenic granuloma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Seborrhoeic keratosis			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Skin papilloma			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Squamous cell carcinoma			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Squamous cell carcinoma of skin			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Vascular disorders			
Jugular vein thrombosis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Artery dissection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Haematoma			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hypertension			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypotension			
subjects affected / exposed	7 / 40 (17.50%)	3 / 9 (33.33%)	0 / 9 (0.00%)
occurrences (all)	8	3	0
Venous thrombosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Phlebitis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	15 / 40 (37.50%)	1 / 9 (11.11%)	4 / 9 (44.44%)
occurrences (all)	20	1	10
Axillary pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Catheter site haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Catheter site inflammation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Catheter site oedema			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Chest pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Chills			

subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Xerosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Pyrexia			
subjects affected / exposed	11 / 40 (27.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	16	1	0
Pain			
subjects affected / exposed	2 / 40 (5.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Oedema peripheral			
subjects affected / exposed	6 / 40 (15.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	8	0	3
Non-cardiac chest pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Mucosal inflammation			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	5	0	0
Malaise			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	3	0	2
Infusion site extravasation			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Hyperthermia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hernia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
General physical health deterioration			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gait disturbance			

subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	7 / 40 (17.50%) 9	3 / 9 (33.33%) 3	1 / 9 (11.11%) 1
Face oedema subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	2 / 9 (22.22%) 2
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Contrast media allergy subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Reproductive system and breast disorders Breast cyst subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Penile erosion subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Hiccups subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 9 (0.00%) 0	1 / 9 (11.11%) 2
Acute respiratory distress syndrome subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	6 / 40 (15.00%) 6	3 / 9 (33.33%) 4	1 / 9 (11.11%) 1

Dysphonia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	1	1	1
Dyspnoea			
subjects affected / exposed	6 / 40 (15.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	6	1	1
Dyspnoea exertional			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	2	1
Epistaxis			
subjects affected / exposed	10 / 40 (25.00%)	1 / 9 (11.11%)	4 / 9 (44.44%)
occurrences (all)	14	1	6
Haemoptysis			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Lower respiratory tract congestion			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Increased viscosity of bronchial secretion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Nasal dryness			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Pleural effusion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pleuritic pain			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Productive cough			

subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Pulmonary embolism			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Pulmonary oedema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Rales			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Respiratory distress			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Upper-airway cough syndrome			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Wheezing			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypoxia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Immune-mediated lung disease			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Lung disorder			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0

Agitation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Anxiety			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	4	0	2
Depression			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hallucination			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	6 / 40 (15.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	6	1	0
Pica			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Restlessness			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	3 / 9 (33.33%)
occurrences (all)	1	0	5
Amylase increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Alanine aminotransferase increased			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	3 / 9 (33.33%)
occurrences (all)	2	0	5
Blood alkaline phosphatase increased			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	4	0	3
SARS-CoV-2 test positive			

subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Blood creatinine increased			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	3 / 9 (33.33%)
occurrences (all)	3	0	6
Blood fibrinogen increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	3
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	3
Blood urea increased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Blood uric acid increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Eosinophil count increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	6	0	5
Neutrophil count increased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Neutrophil count decreased			
subjects affected / exposed	2 / 40 (5.00%)	3 / 9 (33.33%)	1 / 9 (11.11%)
occurrences (all)	7	5	3
Lymphocyte count decreased			

subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	1	2
Haematocrit decreased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gastric pH decreased			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Gamma-glutamyltransferase increased			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	3	0	2
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	0	2	4
Sputum abnormal			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	5 / 40 (12.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	9	1	1
Weight increased			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
White blood cell count decreased			
subjects affected / exposed	3 / 40 (7.50%)	4 / 9 (44.44%)	1 / 9 (11.11%)
occurrences (all)	12	6	3
Injury, poisoning and procedural complications			
Ilium fracture			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Head injury			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Fall			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Eye contusion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Contusion			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Infusion related reaction			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	3	1	1
Traumatic haematoma			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Spinal fracture			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Skin abrasion			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Radiation skin injury			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Tricuspid valve incompetence			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Tachycardia			
subjects affected / exposed	1 / 40 (2.50%)	3 / 9 (33.33%)	0 / 9 (0.00%)
occurrences (all)	1	3	0

Sinus tachycardia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Mitral valve incompetence			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Cardiac failure			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Atrial flutter			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Atrial fibrillation			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Angina pectoris			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Myocarditis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
Ataxia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Dizziness			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	1	3	0
Dizziness postural			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	4	0	1
Headache			

subjects affected / exposed	4 / 40 (10.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	5	1	1
Hypoaesthesia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Motor dysfunction			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Neuralgia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	2	0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 40 (0.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Presyncope			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Restless legs syndrome			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Taste disorder			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Neuropathy peripheral			

subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 9 (11.11%) 1	2 / 9 (22.22%) 2
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Hyperleukocytosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Thrombocytosis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	2	0	2
Thrombocytopenia			
subjects affected / exposed	7 / 40 (17.50%)	2 / 9 (22.22%)	4 / 9 (44.44%)
occurrences (all)	13	3	6
Spontaneous haematoma			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pancytopenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Neutropenia			
subjects affected / exposed	5 / 40 (12.50%)	1 / 9 (11.11%)	5 / 9 (55.56%)
occurrences (all)	7	3	5
Myelosuppression			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Lymphopenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	5
Lymphadenopathy			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Anaemia			
subjects affected / exposed	20 / 40 (50.00%)	6 / 9 (66.67%)	9 / 9 (100.00%)
occurrences (all)	28	12	9

Eosinophilia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Febrile neutropenia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Hypoacusis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Ear discomfort			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Tinnitus			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Eye disorders			
Blepharospasm			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Blepharitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Diplopia			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Xerophthalmia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Visual impairment			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Vision blurred			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Dry eye			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Gastrointestinal disorders			
Cheilitis			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Aphthous ulcer			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Abdominal pain upper			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Abdominal pain lower			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Abdominal discomfort			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Colitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Mouth haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Diarrhoea			
subjects affected / exposed	13 / 40 (32.50%)	3 / 9 (33.33%)	2 / 9 (22.22%)
occurrences (all)	15	3	2

Dry mouth			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	2	0	1
Duodenitis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Melaena			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	2	2	1
Haemorrhoids			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	1	0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Haematochezia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Gingival bleeding			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	0	0	2
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 40 (0.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	0	2	0
Gastritis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Gastric ulcer			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Enteritis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Dysphagia			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Dyspepsia			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	5	0	1
Constipation			
subjects affected / exposed	7 / 40 (17.50%)	6 / 9 (66.67%)	2 / 9 (22.22%)
occurrences (all)	10	10	3
Oral mucosa erosion			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Rectal haemorrhage			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Stomatitis			
subjects affected / exposed	5 / 40 (12.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	5	6	0
Stomatitis haemorrhagic			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Subileus			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Tongue dry			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	7 / 40 (17.50%)	1 / 9 (11.11%)	2 / 9 (22.22%)
occurrences (all)	12	1	4

Nausea			
subjects affected / exposed	21 / 40 (52.50%)	3 / 9 (33.33%)	6 / 9 (66.67%)
occurrences (all)	29	3	11
Oesophageal pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oesophagitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatic cytolysis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Cholestasis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Hepatotoxicity			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Hepatitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Actinic keratosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	3	0	0
Alopecia			
subjects affected / exposed	2 / 40 (5.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Rash			
subjects affected / exposed	7 / 40 (17.50%)	2 / 9 (22.22%)	2 / 9 (22.22%)
occurrences (all)	9	2	3
Dermal cyst			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Dermatitis			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	2
Dermatitis bullous			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Drug eruption			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	5 / 40 (12.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	5	0	3
Eczema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	5	0	8
Erythema			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	6	0	2
Hyperkeratosis			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	4	0	1
Intertrigo			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Keratosis pilaris			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Papule			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Pemphigoid			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Petechiae			

subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	15 / 40 (37.50%)	3 / 9 (33.33%)	6 / 9 (66.67%)
occurrences (all)	22	3	11
Purpura			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Blister			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Rash erythematous			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Rash papular			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Skin discolouration			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Skin hyperpigmentation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	1 / 9 (11.11%)
occurrences (all)	4	6	12
Skin lesion inflammation			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Subcutaneous emphysema			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Toxic skin eruption			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Urticaria			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Xeroderma			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	3
Rash maculo-papular			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	2	0	2
Nephritis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Renal failure			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	4	0	1
Renal impairment			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Urinary retention			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Dysuria			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Endocrine disorders			
Immune-mediated hyperthyroidism			

subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypothyroidism			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	4	0	1
Hyperthyroidism			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	4	0	2
Musculoskeletal and connective tissue disorders			
Neck pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	2 / 9 (22.22%)
occurrences (all)	1	0	2
Arthralgia			
subjects affected / exposed	4 / 40 (10.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	5	2	0
Back pain			
subjects affected / exposed	2 / 40 (5.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	2	1	0
Bone pain			
subjects affected / exposed	0 / 40 (0.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	0	3	0
Immune-mediated myositis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	2	2	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			

subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Myalgia			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	2 / 9 (22.22%)
occurrences (all)	1	3	2
Myositis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Osteonecrosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	2 / 9 (22.22%)
occurrences (all)	3	1	2
Spinal pain			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Herpes simplex			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	1 / 40 (2.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	1	1	0
Folliculitis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Device related infection			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0

Cellulitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Candida infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Bronchitis			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Abscess intestinal			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	3	0	1
Furuncle			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Urinary tract infection			
subjects affected / exposed	4 / 40 (10.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	4	0	0
Paronychia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oral herpes			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Oral fungal infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Oesophageal candidiasis			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	0	0	1
Nasopharyngitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hordeolum			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Pneumonia pseudomonal			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Rash pustular			
subjects affected / exposed	2 / 40 (5.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	2	0	0
Rhinitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Sepsis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Skin infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 40 (0.00%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	0	1	0
Tooth infection			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Periodontitis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Yersinia bacteraemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0

Wound infection subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Metabolism and nutrition disorders			
Hyperkalaemia subjects affected / exposed occurrences (all)	2 / 40 (5.00%) 2	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Hypermagnesaemia subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Hypernatraemia subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Hyperuricaemia subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Hypoalbuminaemia subjects affected / exposed occurrences (all)	3 / 40 (7.50%) 3	0 / 9 (0.00%) 0	1 / 9 (11.11%) 2
Hypocalcaemia subjects affected / exposed occurrences (all)	0 / 40 (0.00%) 0	1 / 9 (11.11%) 1	0 / 9 (0.00%) 0
Hypochloraemia subjects affected / exposed occurrences (all)	2 / 40 (5.00%) 2	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Cell death subjects affected / exposed occurrences (all)	1 / 40 (2.50%) 1	0 / 9 (0.00%) 0	0 / 9 (0.00%) 0
Decreased appetite			

subjects affected / exposed	7 / 40 (17.50%)	3 / 9 (33.33%)	4 / 9 (44.44%)
occurrences (all)	9	4	4
Dehydration			
subjects affected / exposed	2 / 40 (5.00%)	2 / 9 (22.22%)	0 / 9 (0.00%)
occurrences (all)	2	4	0
Diabetes mellitus			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Folate deficiency			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Hypercalcaemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	1	0	1
Hyperglycaemia			
subjects affected / exposed	3 / 40 (7.50%)	1 / 9 (11.11%)	0 / 9 (0.00%)
occurrences (all)	3	2	0
Hypokalaemia			
subjects affected / exposed	6 / 40 (15.00%)	3 / 9 (33.33%)	1 / 9 (11.11%)
occurrences (all)	9	6	2
Hyponatraemia			
subjects affected / exposed	3 / 40 (7.50%)	0 / 9 (0.00%)	1 / 9 (11.11%)
occurrences (all)	4	0	1
Hypophosphataemia			
subjects affected / exposed	1 / 40 (2.50%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	1	2	1
Hypoproteinaemia			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Iron deficiency			
subjects affected / exposed	0 / 40 (0.00%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	0	0	0
Lactic acidosis			
subjects affected / exposed	1 / 40 (2.50%)	0 / 9 (0.00%)	0 / 9 (0.00%)
occurrences (all)	1	0	0
Hypomagnesaemia			

subjects affected / exposed	3 / 40 (7.50%)	2 / 9 (22.22%)	1 / 9 (11.11%)
occurrences (all)	4	5	1

Non-serious adverse events	Cohort D: Bintrafusp alfa + Docetaxel		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 12 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cancer pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Keratoacanthoma			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Papilloma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pyogenic granuloma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Seborrhoeic keratosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin papilloma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Squamous cell carcinoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Squamous cell carcinoma of skin			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vascular disorders			

Jugular vein thrombosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Artery dissection subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Deep vein thrombosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Haematoma subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Hypertension subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Hypotension subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Venous thrombosis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Phlebitis subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	7 / 12 (58.33%) 10		
Axillary pain subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Catheter site haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Catheter site inflammation			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Catheter site oedema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Chills			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Xerosis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	6		
Pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Non-cardiac chest pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Malaise			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Infusion site extravasation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hyperthermia			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hernia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
General physical health deterioration			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Gait disturbance			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Face oedema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Seasonal allergy			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Contrast media allergy			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Reproductive system and breast disorders			
Breast cyst			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Penile erosion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Hiccups			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Acute respiratory distress syndrome			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Dysphonia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	5 / 12 (41.67%)		
occurrences (all)	6		
Dyspnoea exertional			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	5		
Haemoptysis			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	4		
Lower respiratory tract congestion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Increased viscosity of bronchial secretion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nasal dryness			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oropharyngeal pain			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pleuritic pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pulmonary oedema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rales			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Respiratory distress			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rhinorrhoea			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Upper-airway cough syndrome			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypoxia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Immune-mediated lung disease			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Lung disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Agitation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hallucination			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Insomnia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pica			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Restlessness			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Amylase increased			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood creatinine increased			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Blood fibrinogen increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood urea increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood uric acid increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eosinophil count increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Platelet count decreased			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Neutrophil count increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Neutrophil count decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Haematocrit decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gastric pH decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sputum abnormal			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Weight increased			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Ilium fracture			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Head injury			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eye contusion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Contusion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Infusion related reaction			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Traumatic haematoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Spinal fracture			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin abrasion			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Radiation skin injury			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Tricuspid valve incompetence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Sinus tachycardia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Mitral valve incompetence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cardiac failure			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Atrial flutter			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Atrial fibrillation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Angina pectoris			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Myocarditis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Ataxia			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Dizziness postural			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Hypoaesthesia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Motor dysfunction			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neuralgia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Paraesthesia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Peripheral motor neuropathy			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Peripheral sensory neuropathy			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Presyncope			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Restless legs syndrome			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Taste disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperleukocytosis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Thrombocytosis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Thrombocytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Spontaneous haematoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pancytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		

Myelosuppression subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Lymphopenia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Lymphadenopathy subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Anaemia subjects affected / exposed occurrences (all)	9 / 12 (75.00%) 9		
Eosinophilia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Febrile neutropenia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Ear and labyrinth disorders Hypoacusis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Ear discomfort subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Tinnitus subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Eye disorders Blepharospasm subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Blepharitis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Diplopia			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Xerophthalmia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Visual acuity reduced			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Lacrimation increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Cheilitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Aphthous ulcer			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Abdominal pain lower			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		

Abdominal discomfort			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Colitis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Mouth haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	6 / 12 (50.00%)		
occurrences (all)	10		
Dry mouth			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	4		
Duodenitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Melaena			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Haemorrhoids			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Haematochezia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gingival bleeding			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Gastrointestinal haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Gastritis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Gastric ulcer subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Enteritis subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Dysphagia subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Dyspepsia subjects affected / exposed occurrences (all)	1 / 12 (8.33%) 1		
Constipation subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2		
Oral mucosa erosion subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Oral pain subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Rectal haemorrhage subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		
Stomatitis subjects affected / exposed occurrences (all)	2 / 12 (16.67%) 2		
Stomatitis haemorrhagic subjects affected / exposed occurrences (all)	0 / 12 (0.00%) 0		

Subileus			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tongue dry			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Vomiting			
subjects affected / exposed	5 / 12 (41.67%)		
occurrences (all)	6		
Nausea			
subjects affected / exposed	5 / 12 (41.67%)		
occurrences (all)	5		
Oesophageal pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Oesophagitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatic cytolysis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cholestasis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hepatotoxicity			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hepatitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			

Actinic keratosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Alopecia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Rash			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Dermal cyst			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dermatitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dermatitis bullous			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Drug eruption			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Hyperkeratosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Intertrigo			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Keratosis pilaris			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Papule			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pemphigoid			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Petechiae			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Purpura			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blister			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash erythematous			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Rash papular			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Rash pruritic			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin discolouration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Skin hyperpigmentation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin lesion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin lesion inflammation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Subcutaneous emphysema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Toxic skin eruption			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Xeroderma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Haematuria			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Nephritis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Renal failure			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Renal impairment			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urinary retention			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dysuria			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Endocrine disorders			
Immune-mediated hyperthyroidism			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypothyroidism			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperthyroidism			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Neck pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Arthralgia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Back pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Bone pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Immune-mediated myositis			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Musculoskeletal pain			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	5		
Myalgia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Myositis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Osteonecrosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Spinal pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Gastroenteritis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Herpes simplex			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Fungal skin infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Device related infection			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Candida infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Abscess intestinal			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Gingivitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Furuncle			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Paronychia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Oral fungal infection			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oral candidiasis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oesophageal candidiasis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hordeolum			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pneumonia pseudomonal			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sepsis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Staphylococcal infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Periodontitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Yersinia bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Wound infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypermagnesaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypernatraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			

subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Hypocalcaemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypochloraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cell death			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Decreased appetite			
subjects affected / exposed	6 / 12 (50.00%)		
occurrences (all)	6		
Dehydration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Diabetes mellitus			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Folate deficiency			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypercalcaemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hyperglycaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Hyponatraemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypophosphataemia			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypoproteinaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Iron deficiency			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Lactic acidosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypomagnesaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
02 July 2019	Key changes to the protocol were done to clarify eligibility criteria, to modify nonserious adverse events of special interest reporting and to update safety profile of bintrafusp alfa according to Investigators brochure.
12 November 2019	The purpose of the amendment was to add additional 3 cohorts to explore the safety and efficacy of bintrafusp alfa with new anti-cancer agents.
22 December 2021	The primary purpose of this amendment was to align with the Investigator Brochure and to update the risk classification and minimization measures.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported